CUT Protocol
Retatrutide R50 Precision Start Pen
Eight weeks of precision-guided Retatrutide optimization.
Key Attributes
- Complete 8-week Retatrutide onboarding in a single pen — no mid-protocol pen change
- Triple-receptor agonist: simultaneous GLP-1, GIP, and glucagon activation
- 200 precision clicks at 0.25 mg — full titration range covered
- Most comprehensive Retatrutide starting protocol available in Bangkok and Thailand
- European-sourced, cold-chain maintained, quality-controlled preparation
Technical Specifications
Biohackr.Labs provides product education, protocol guidance, and private client support. Information on this website is not medical advice and does not replace consultation with a licensed healthcare professional.
What's Included
Premium hard case.
Everything included.
Every Biohackr.Labs pen ships in our premium white hard case — holographic logo, foam-fitted interior. Inside: the precision pen, ten individually sealed 31G 8mm micro needles, and all documentation needed to begin your protocol correctly.
Precision pen
Pre-filled, batch quality-controlled pen system ready at your confirmed starting dose.
10× 31G micro needles
31G 8mm individually sealed sterile micro needles. Ten included as standard with every pen.
Protocol card
Starting dose, titration schedule, session guidance, and what to expect — specific to your protocol.
Batch QC documentation
Batch reference, preparation date, and compound specification. Not boilerplate — specific to your order.
Storage & handling guide
Temperature requirements, travel guidance, and handling notes with Bangkok climate context.
Private support access
WhatsApp, LINE, email, and My Account support throughout your protocol cycle.
Professional Packing
Strictly packed for
cold-chain delivery.
Peptide pen formulations are temperature-sensitive. Every order is packed as a refrigerated product and handled under strict cold-chain conditions — insulated temperature-control packaging with cold packs maintained at the standard refrigerated range of 2–8°C wherever available during transit.
Refrigerated cold-chain transport
Peptide pens are handled as refrigerated products throughout transit. Intended transport condition is controlled cold-chain delivery at 2–8°C wherever available. Available in supported cold-chain delivery areas only.
Temperature-control packaging
Insulated temperature-control packaging with cold packs engineered to maintain the product in the refrigerated range from preparation to handover — anywhere in Thailand with cold-chain delivery coverage.
Refrigerate immediately on receipt
Transfer to refrigerated storage the moment you receive your order. Do not leave unattended or delay collection. Tamper-evident sealing confirms product integrity at handover.
Step 01
Protocol Overview
“Eight weeks of precision-guided Retatrutide optimization.”
The R50 Precision Start Pen delivers 50 mg of Retatrutide across a complete 8-week guided onboarding protocol — the full arc from first dose to established metabolic response. With 200 precision clicks at 0.25 mg each, the R50 provides the volume needed to titrate through the early dose range, identify your individual response threshold, and enter a stable maintenance phase. The preferred starting pen for clients who want a structured full-course experience from the outset.
Step 02
Mechanism of Action
Retatrutide's triple-receptor activity (GLP-1, GIP, glucagon) produces progressive metabolic adaptation over the course of an 8-week protocol. The first 2–4 weeks typically establish appetite regulation; weeks 4–8 typically show body composition changes as metabolic efficiency improves. The R50's 200-click volume allows for full titration from entry dose through to an individual's established dose without interruption between pens.
Suggested Use
One weekly subcutaneous administration. Begin titration from 0.5 mg in week one and increase as guided. Full protocol guidance provided through order review.
Who This Protocol Is For
For clients in Bangkok and throughout Thailand seeking a complete, uninterrupted 8-week Retatrutide protocol from a single pen. Suitable for those who prefer a structured long-form approach and plan to transition to maintenance dosing after completing the onboarding arc.
Storage — Bangkok & Thailand
Refrigerate between 2–8°C. Thailand's heat accelerates peptide degradation — refrigeration is non-negotiable for a pen you will use over 8 weeks. Keep sealed until first use.
Delivery — Thailand
Peptide pens are shipped under strict cold-chain handling — handled as refrigerated products at 2–8°C wherever available. Available in supported cold-chain delivery areas only.
Refrigerate immediately on receipt. You must be present to receive the delivery directly.
Potential Side Effects
- GI effects (nausea, vomiting, diarrhoea) — most common; dose-dependent and typically improve with careful titration
- Reduced appetite — expected mechanism effect; can be significant at therapeutic doses
- Injection site reactions — transient redness or discomfort at administration site
- Fatigue — reported during dose escalation phases
- Dysesthesia (tingling or altered skin sensation) — observed in approximately 21% of participants at 12 mg in Phase 3 trial data
- Cardiac effects under active investigation in ongoing Phase 3 trials — prior medical suitability review required
Science Hub
Order Review Required
All Biohackr.Labs orders are reviewed before confirmation. Dosing and administration are confirmed before fulfilment where required.
Enquire on WhatsAppAdd LINEThe Compound
What Is Retatrutide?
Retatrutide (LY3437943) is a synthetic once-weekly peptide developed by Eli Lilly — the first triple hormone receptor agonist to enter Phase 3 clinical trials. Where semaglutide activates one receptor and tirzepatide activates two, retatrutide simultaneously activates three: GLP-1, GIP, and glucagon. This triple mechanism produces compounding effects on appetite, fat metabolism, and energy expenditure that neither dual nor single agonists can replicate.
By targeting three complementary metabolic pathways at once, retatrutide addresses the biology of excess weight from multiple angles simultaneously. The result is weight loss outcomes that exceed what single or dual agonist compounds can achieve — including outcomes comparable to bariatric surgery in a subset of patients.
Semaglutide
Ozempic / Wegovy
Mechanism
GLP-1 only
Peak weight loss
~13.9%
Tirzepatide
Mounjaro / Zepbound
Mechanism
GLP-1 + GIP
Peak weight loss
~17.8–20.9%
Retatrutide
Pending (LY3437943)
Mechanism
GLP-1 + GIP + Glucagon
Peak weight loss
~25–30.3%
Cross-trial comparisons have inherent limitations. A head-to-head trial would be required for definitive conclusions.
Triple Mechanism
What Each Agonist Does
GLP-1
Glucagon-Like Peptide-1
Role
Appetite and insulin regulation
Slows gastric emptying to reduce caloric intake, suppresses appetite signals in the hypothalamus, and stimulates glucose-dependent insulin secretion. GLP-1 agonism is the foundation of semaglutide and tirzepatide — and the primary mechanism of all incretin-based compounds.
Key Effect
Appetite reduction + insulin sensitivity
Also in: Semaglutide, Tirzepatide
GIP
Glucose-dependent Insulinotropic Polypeptide
Role
Nutrient partitioning and fat cell metabolism
Enhances insulin sensitivity in peripheral tissues, modulates how the body partitions incoming calories between storage and use, and appears to amplify the appetite-suppressing effects of GLP-1 agonism. GIP is the second receptor targeted by tirzepatide — and a key contributor to its weight loss advantage over semaglutide.
Key Effect
Enhanced insulin sensitivity + fat cell regulation
Also in: Tirzepatide
Glucagon
Glucagon Receptor
Role
Energy expenditure and direct liver fat clearance
The critical differentiator. Glucagon receptor activation directly stimulates the liver to burn stored fat (fatty acid oxidation) and suppresses new fat synthesis (de novo lipogenesis). It also increases basal metabolic rate and thermogenesis — meaning the body burns more calories at rest. No approved obesity medication targets this receptor. It is the mechanism responsible for retatrutide's unprecedented liver fat reduction data.
Key Effect
Increased energy expenditure + hepatic fat clearance
Also in: Unique to Retatrutide among approved/late-stage compounds
Beyond Weight Loss
Emerging Benefits From Clinical Data
Clinical trial data surfacing across the TRIUMPH program suggests retatrutide may offer systemic benefits beyond weight management — driven by the glucagon receptor component that neither semaglutide nor tirzepatide possess.
Metabolic Liver Disease (MASLD/MASH)
The glucagon receptor component drives direct hepatic fat oxidation — the liver burns its stored triglycerides. Phase 2a data (Nature Medicine, 2024) showed 86% liver fat reduction and 90% complete resolution, unprecedented for any pharmacological agent. Phase 3 MASLD/MASH-specific trials are underway.
Knee Osteoarthritis
TRIUMPH-4 (Dec 2025) demonstrated substantial reduction in knee pain and improved physical function in patients with obesity and osteoarthritis — the first Phase 3 drug trial to show this combination of weight and pain outcomes simultaneously.
Systemic Inflammation
TRIUMPH-1 investigators noted "clear improvements in assessed cardiometabolic health measures" including inflammatory markers. The triple receptor mechanism appears to address metabolic inflammation through multiple pathways — weight-independent of the pure weight loss effect.
Insulin Resistance
Significant reductions in HOMA-IR (the standard measure of insulin resistance) have been observed across both Phase 2 and Phase 3 data, suggesting potential utility in pre-diabetic and early diabetic metabolic profiles beyond weight alone.
Sleep Apnoea
A dedicated TRIUMPH trial arm is evaluating retatrutide in adults with obesity and moderate-to-severe obstructive sleep apnoea. Results expected 2026. GLP-1 class compounds have shown sleep apnoea benefit proportional to weight loss; the triple mechanism may amplify this further.
Cardiovascular Outcomes
TRIUMPH-3 is studying retatrutide specifically in adults with established cardiovascular disease — one of the highest-risk obesity populations. The SELECT trial established semaglutide reduces major cardiovascular events by ~20%; whether triple agonism improves this further is the core question. Results expected 2026.
All emerging benefit data is from Phase 2 or Phase 3 clinical trial publications and official Eli Lilly announcements. Retatrutide is investigational. Benefits described are not confirmed clinical indications.
Live Research
TRIUMPH Trial Tracker
Last updated
June 30, 2026
Eli Lilly TRIUMPH Phase 3 · published highlights + active registry watch
25.0% avg weight loss at 80 weeks (12 mg). 30.3% at 104 weeks. 45.3% lost >30% bodyweight.
ClinicalTrials.gov lists the study as active, not recruiting; no posted results at last review.
ClinicalTrials.gov lists the study as active, not recruiting; evaluates obesity with cardiovascular disease.
28.7% avg weight loss at 68 weeks (12 mg). Substantial knee pain reduction.
Large event-driven Phase 3 outcomes study; ClinicalTrials.gov lists estimated completion in 2029.
FDA submission anticipated 2026–2027 following full TRIUMPH program readouts. · ClinicalTrials.gov API checked June 30, 2026. Review monthly, and immediately after Lilly readouts or registry updates. Data is reviewed against official registries, Eli Lilly releases, and peer-reviewed publications. Retatrutide is investigational and not approved for clinical use.
Key Statistics
Phase 3 TRIUMPH Data Highlights
30.3%
Average weight loss at 104 weeks
12 mg dose, TRIUMPH-1 — comparable to bariatric surgery outcomes
Eli Lilly, May 2026
45.3%
Patients losing >30% body weight
12 mg dose — a threshold historically achievable only through surgery
TRIUMPH-1, May 2026
70.3 lbs
Average weight lost at 80 weeks
12 mg dose, TRIUMPH-1 — highest weight loss for any non-surgical intervention in Phase 3
Eli Lilly, May 2026
86%
Liver fat reduction at 48 weeks
12 mg dose, Phase 2a liver sub-study — unprecedented for any pharmacological compound
Nature Medicine, 2024
90%
Patients achieving complete liver fat resolution
<5% liver fat — effectively clearing hepatic steatosis in 9 of 10 participants
Nature Medicine, 2024
5,800+
Participants enrolled in TRIUMPH program
Across four global registrational trials — the largest retatrutide trial program to date
Eli Lilly, 2026
Same Collection
Related CUT Protocols
My Account
Premium imported peptide pens in Bangkok.
Reviewed My Account ordering · European-sourced · Quality-controlled · Thailand delivery
Enquire About Retatrutide R50 Precision Start Pen